AR011170A1 - Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen - Google Patents

Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen

Info

Publication number
AR011170A1
AR011170A1 ARP980100871A ARP980100871A AR011170A1 AR 011170 A1 AR011170 A1 AR 011170A1 AR P980100871 A ARP980100871 A AR P980100871A AR P980100871 A ARP980100871 A AR P980100871A AR 011170 A1 AR011170 A1 AR 011170A1
Authority
AR
Argentina
Prior art keywords
aril
hydrogen
atropoisomers
halo
formula
Prior art date
Application number
ARP980100871A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR011170A1 publication Critical patent/AR011170A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Atropoisomeros de 2-(aril o heteroaril)-3-aril-4(3H)-quinazolinonas de formula (I) donde R2 es un grupo fenilo de la formula Ph2 o un heterociclo decinco o seis miembros; elegido del grupo formado por los grupos de formula (II), (III) o (IV), R3es hidrogeno, halo, -CN, -NO2, CF3, alquilo(C1-C6) o alcoxi(C1-C6); R5 es hidrogeno, alquilo(C1-C6), halo, CF3, alcoxi(C1-C6) o alquiltio (C1-C6); R6 es hidrogeno o halo; R7 es hidrogeno o halo; R8 es hidrogeno ohalo. Se refiere a atropoisomeros de3-aril-4(3H)-quinazolinonas de la formula (I), descriptos más adelante, a sus sales farmacéuticamente aceptables y acomposiciones farmacéuticas y procedimientos para el tratamiento de afecciones neurodegenerativas y relacionadas con traumas del SNC.
ARP980100871A 1997-02-28 1998-02-26 Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen AR011170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
AR011170A1 true AR011170A1 (es) 2000-08-02

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100871A AR011170A1 (es) 1997-02-28 1998-02-26 Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen

Country Status (40)

Country Link
US (1) US6306864B1 (es)
EP (1) EP0968194B1 (es)
JP (1) JP2000509731A (es)
KR (1) KR100358636B1 (es)
CN (1) CN1248248A (es)
AP (1) AP859A (es)
AR (1) AR011170A1 (es)
AT (1) ATE267817T1 (es)
AU (1) AU744028B2 (es)
BG (1) BG103689A (es)
BR (1) BR9807872A (es)
CA (1) CA2282277C (es)
DE (1) DE69824157T2 (es)
DK (1) DK0968194T3 (es)
DZ (1) DZ2440A1 (es)
EA (1) EA001963B1 (es)
ES (1) ES2219866T3 (es)
GT (1) GT199800038A (es)
HR (1) HRP980106A2 (es)
HU (1) HUP0000914A3 (es)
ID (1) ID22711A (es)
IL (1) IL130900A0 (es)
IS (1) IS1952B (es)
MA (1) MA24484A1 (es)
NO (1) NO313630B1 (es)
NZ (1) NZ336628A (es)
OA (1) OA11089A (es)
PA (1) PA8447001A1 (es)
PE (1) PE58399A1 (es)
PL (1) PL335418A1 (es)
PT (1) PT968194E (es)
SK (1) SK113299A3 (es)
TN (1) TNSN98035A1 (es)
TR (1) TR199902093T2 (es)
TW (1) TW504508B (es)
UA (1) UA61097C2 (es)
UY (1) UY24897A1 (es)
WO (1) WO1998038173A1 (es)
YU (1) YU41299A (es)
ZA (1) ZA981666B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL330042A1 (en) 1996-05-15 1999-04-26 Pfizer Novel 2,3-disubstituted 4(3h)-quinazolynones
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
WO2001081346A2 (en) * 2000-04-25 2001-11-01 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ATE420862T1 (de) 2000-06-12 2009-01-15 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
IL154350A0 (en) 2000-08-18 2003-09-17 Ajinomoto Kk New phenylalanine derivatives
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
CN1832941A (zh) * 2003-08-08 2006-09-13 尤利塞斯药品公司 作为抗菌剂的卤代喹唑啉基硝基呋喃类化合物
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
TWI409070B (zh) 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節trpv3功能之化合物
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US8440677B2 (en) 2009-03-24 2013-05-14 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
UY34656A (es) 2012-03-05 2013-10-31 Gilead Calistoga Llc Polimorfos de (s)?2?(1?(9h?purin?6?ilamino)propil)?5?fluor?3?fenilquinazolin?4(3h)?ona, composición y método de preparación
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
BR112016028642A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
BR112021010953A2 (pt) 2018-12-14 2021-08-24 Eisai R&D Management Co., Ltd. Formulações farmacêuticas de base aquosa de compostos de 1,2-di-hidropiridina
EP4096661A4 (en) 2020-01-29 2024-03-06 Kamari Pharma Ltd COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) * 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
PL330042A1 (en) * 1996-05-15 1999-04-26 Pfizer Novel 2,3-disubstituted 4(3h)-quinazolynones

Also Published As

Publication number Publication date
NZ336628A (en) 2001-03-30
AP9801199A0 (en) 1998-03-31
HUP0000914A2 (hu) 2001-04-28
ATE267817T1 (de) 2004-06-15
AU744028B2 (en) 2002-02-14
NO994177L (no) 1999-08-27
ES2219866T3 (es) 2004-12-01
IL130900A0 (en) 2001-01-28
IS5140A (is) 1999-07-30
BG103689A (bg) 2000-11-30
PL335418A1 (en) 2000-04-25
HUP0000914A3 (en) 2001-09-28
UA61097C2 (uk) 2003-11-17
DE69824157D1 (de) 2004-07-01
CA2282277C (en) 2005-10-11
DE69824157T2 (de) 2004-10-14
KR20000075814A (ko) 2000-12-26
NO994177D0 (no) 1999-08-27
GT199800038A (es) 1999-08-13
OA11089A (en) 2003-09-22
EA199900693A1 (ru) 2000-02-28
EP0968194A1 (en) 2000-01-05
SK113299A3 (en) 2001-05-10
YU41299A (sh) 2002-09-19
ZA981666B (en) 1999-08-27
JP2000509731A (ja) 2000-08-02
AU5676898A (en) 1998-09-18
AP859A (en) 2000-07-21
NO313630B1 (no) 2002-11-04
TNSN98035A1 (fr) 2005-03-15
TW504508B (en) 2002-10-01
EA001963B1 (ru) 2001-10-22
HRP980106A2 (en) 1999-02-28
US6306864B1 (en) 2001-10-23
IS1952B (is) 2004-10-13
CN1248248A (zh) 2000-03-22
CA2282277A1 (en) 1998-09-03
TR199902093T2 (xx) 1999-12-21
UY24897A1 (es) 2000-12-29
DK0968194T3 (da) 2004-08-16
PA8447001A1 (es) 2000-05-24
MA24484A1 (fr) 1998-10-01
PT968194E (pt) 2004-08-31
BR9807872A (pt) 2000-03-21
DZ2440A1 (fr) 2003-01-11
EP0968194B1 (en) 2004-05-26
WO1998038173A1 (en) 1998-09-03
ID22711A (id) 1999-12-09
KR100358636B1 (ko) 2002-10-31
PE58399A1 (es) 1999-06-16

Similar Documents

Publication Publication Date Title
AR011170A1 (es) Atropoisomeros de 2-(aril o heteroaril)-3-aril-4 (3h)-quinazolinonas y composiciones farmaceuticas que los contienen
AR034119A1 (es) Compuestos de 5-alquilpirido pirimidinas, composicion farmaceutica, uso para prepararla y metodo para inhibir cinasas con dichos compuestos
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
AR033594A1 (es) Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
CO5160347A1 (es) Derivados de acido carbamico
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
GT199700049A (es) Nueva 4(3h)-quinazolinonas 2,3 disustituidas
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
DE3853577T2 (de) Benzyliden-Malononitril-Derivate zur Hemmung von proliferativen Prozessen in Säugetierzellen.
EE04308B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
CO5550439A2 (es) Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
SE8802412L (sv) Tiokarbamidderivat
CO5180631A1 (es) Derivados de bencimidazol sustituidos con aminocarbonilo, procedimientos para su preparacion y su utilizacion como medicamentos
DK0707570T3 (da) Isoquinolinderivater som terapeutiske midler
AR022927A1 (es) Inhibidores de proteasas
DK0612314T3 (da) 2-pyrazinylethylaminderivater og deres anvendelse som lægemidler
DE69414112T2 (de) Pyridazinon derivate mit pharmazeutischer wirkung
UY26147A1 (es) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
ES2055651B1 (es) Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.
AR001786A1 (es) Composición farmacéutica para tratar y prevenir enfermedades mediante la regulación de apoptosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal